Development of Efficiently Quantitative Analysis Targeting <i>α</i>-Galactosylceramide in FreeStyle 293-F Cells
α-Galactosylceramide (α-GalCer), a synthetic lipid that activates natural killer T cells, has been studied for administration as an active component of artificial adjuvant vector cells (aAVCs) for cancer therapy. A quantification method for α-GalCer content in the cells is essential to ensure the antitumor effect of aAVCs. In this study, a new analytical procedure was established using LC and tandem MS, with a lipid extraction method and internal standard method, and its analytical validation was performed. Furthermore, the procedure was applied to determine α-GalCer content in α-GalCer-loaded model cells, which are the original vector cells in aAVCs.
Authors
- Yuichiro Oba (ORCID: https://orcid.org/0000-0002-9213-6479)
- Kei Motonaga
- Koji Nishimura (ORCID: https://orcid.org/0000-0003-0507-8184)
- Kentaro Iwata (ORCID: https://orcid.org/0000-0001-7613-7722)
- Kanae Otsutomo
Institutions
- Astellas Pharma (Japan) (JP)
Publication Details
- Journal
- Chemical and Pharmaceutical Bulletin
- Published
- 2025-06-19
- DOI
- https://doi.org/10.1248/cpb.c25-00161
- Primary Topic
- Glycosylation and Glycoproteins Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Astellas Pharma
- Astellas Foundation for Research on Metabolic Disorders